Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $73.3152W HIGH $106.33
Volume
855.59 K
Value Traded
584.23 M
Short % Float
1.35%
+1.59%Week
-4.51%1 Month
+4.63%3 Month
+0.62%6 Month
-38.26%5 Year
+24,973.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
114.02 B
EPS (TTM)
4.09
P/E Ratio
21.46
Ent. Value
103.43 B
Total Shares
1.28 B
Float Shares
1.28 B
Insiders
0.09%
Institutions
89.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MDT Catalyst Timeline
Dated clinical, regulatory and corporate events for Medtronic plc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medtronic plc.
834Total events
22Upcoming
346Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
●Corporate ApprovalCorporate
Final exchange ratio of 4.5939 set for MiniMed split-off exchange offer
●Management ChangeCorporate
Lindsay Boyle named VP of Commercial Operations at Blink Anesthesia
▲Reimbursement / PricingPost-Market
AMA approves Category I CPT codes for Symplicity Spyral
uncontrolled hypertensionsource ↗
▲Reimbursement / PricingAltavivaApprovedPost-Market
AMA approves Category I CPT codes for Altaviva
urge urinary incontinencesource ↗
▲EU ApprovalEx-US Regulatory
CE Mark for PulseSelect ProxBox Adapter with Proximity Indicator software
cardiac arrhythmiassource ↗
▲FDA ApprovalFDA Decision
FDA clearance for Affera Prism-2 Mapping Software
cardiac arrhythmiassource ↗
▲EU ApprovalEx-US Regulatory
CE Mark for PulseSelect ProxBox Adapter with Proximity Indicator software
cardiac arrhythmiassource ↗
▲FDA ApprovalFDA Decision
FDA clears LigaSure RAS Maryland jaw device for use with Hugo RAS system
vessel sealing in robotic-assisted surgerysource ↗
▲FDA ApprovalFDA Decision
FDA clears LigaSure RAS Maryland jaw device for use with Hugo RAS system
robotic-assisted surgery (vessel sealing)source ↗
▲Partnership / LicenseCorporate
Sonus Microsystems and Medtronic announce collaboration to integrate Sonus Patch with Medtronic monitoring technology
early-onset preeclampsiasource ↗
●Corporate ApprovalCorporate
Medtronic commenced exchange offer to split off at least 80.1% of MiniMed shares
●Oral PresentationPresentation
Medtronic to present at 2026 Wells Fargo Healthcare Conference
▲Partnership / LicenseCorporate
Medtronic announces strategic partnership with Cornerstone Robotics including $700M investment and ex-US distribution rights for Sentire system
▼Equity OfferingCorporate
Medtronic to make strategic investment of approximately $700 million in Cornerstone Robotics
▲Partnership / LicenseCorporate
Medtronic announces strategic partnership with Cornerstone Robotics
▲EU ApprovalEx-US Regulatory
Expanded CE Mark indication for Affera and Sphere-9 for ventricular arrhythmias
ventricular arrhythmiassource ↗
▲FDA ApprovalFDA Decision
FDA clearance for Touch Surgery Aide next generation computing platform
▲Label ExpansionFDA Decision
Expanded CE Mark indication for Affera/Sphere-9 for ventricular arrhythmias
ventricular arrhythmiassource ↗
▲Breakthrough Therapy DesignationDesignation
FDA granted Breakthrough Device Designation for Sphere-9 for ventricular arrhythmias
ventricular arrhythmiassource ↗
▲Quarterly UpdateCorporate
Medtronic reports Q4 FY26 revenue of $9.8B, GAAP EPS $0.96, non-GAAP EPS $1.55
▲Partnership / LicenseCorporate
Medtronic announces strategic investments in Beluga Medical and CardioACC for ICE catheter technologies
●NDA SubmissionRegulatory Filing
510(k) filings for Hugo RAS system in general surgery and gynecologic specialties
general surgery and gynecological proceduressource ↗
●NDA SubmissionRegulatory Filing
510(k) filing for LigaSure RAS Maryland instrument on Hugo RAS system
▲FDA Filing AcceptedRegulatory Filing
FDA clearance for ProGrip Advanced mesh for robotic-assisted ventral hernia repair
robotic-assisted ventral hernia repairsource ↗
▲Enrollment CompleteTrial
Enrollment completed in Embrace Gynecology IDE study for Hugo RAS system
gynecologic proceduressource ↗
▲FDA ApprovalFDA Decision
Secured FDA Clearance for Spine, Cranial and ENT indications for Stealth AXiS Surgical System
Spine, Cranial and ENTsource ↗
●NDA SubmissionRegulatory Filing
Filed submission to U.S. FDA for Hugo™ RAS for general surgery and gynecologic indications
general surgery and gynecologicsource ↗
▲FDA Filing AcceptedRegulatory Filing
Secured FDA Clearance for Spine, Cranial and ENT indications for Stealth AXiS™ Surgical System
Spine, Cranial and ENTsource ↗
▲EU ApprovalEx-US Regulatory
Received CE Mark for Spine and Cranial indications for Stealth AXiS™ Surgical System
Spine and Cranialsource ↗
▲FDA Filing AcceptedRegulatory Filing
510(k) submissions to expand Hugo RAS system into general and gynecologic specialties
general and gynecologic specialtiessource ↗
●NDA SubmissionRegulatory Filing
510(k) submissions to expand Hugo RAS system into general and gynecologic specialties
general and gynecologic specialtiessource ↗
◆AcquisitionCorporate
Announced intention to acquire Scientia Vascular in Neurovascular and SPR Therapeutics in Neuromodulation
▲Other Regulator MilestoneSentire™ApprovedEx-US Regulatory
Sentire™ surgical system received CE marking in EU and HSA approval in Singapore
minimally invasive general, gynecological, thoracic, and urological proceduressource ↗
▲EU ApprovalSentire™ApprovedEx-US Regulatory
Sentire received CE Mark
minimally invasive general, gynecologic, thoracic, and urologic surgical proceduressource ↗
▲Other Regulator MilestoneSentire™ApprovedEx-US Regulatory
Sentire surgical system received approval from Singapore Health Sciences Authority
minimally invasive general, gynecologic, thoracic, and urologic surgical proceduressource ↗
▲EU ApprovalSentire™ApprovedEx-US Regulatory
Sentire™ surgical system received CE marking in the European Union
minimally invasive general, gynecological, thoracic, and urological proceduressource ↗
Past FDA Catalysts and PDUFA Decisions
How MDT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2020-04-28 | Sinuva (mometasone furoate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D30 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
3
Drugs Scored
-
rNPV / MCap
Top 69%
Large Pharma(rank 454 of 658)
Percentile Rank
Medtronic plc. faces pipeline headwinds (30/100), with 3 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every MDT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Sphere-9 catheter Breakthrough | recurrent sustained monomorphic ventricular tachycardia (VT) | Preclinical | 2026-04-25 | In a six-month follow-up of patients treated with the Sphere-9 catheter for recurrent sustained monomorphic ventricular tachycardia, 65.5% remained free from VT recurrence, indicating promising efficacy in this early feasibility study.Read More | Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic...Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KIIL HARRY SKIPOfficer (EVP & President Cardiovascular) | Sell | -1,483 42,186 held | $93.65 | 09/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MDT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 0.6 % (-81.3 %) | 15.65 M | 200.00 K | -70.37% ( -475.00 K) |
MDT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-06 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MDT ranks across every disease it competes in
Competitive Position is a premium feature
See how MDT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMDT News
MDT▲ +1.8%today
Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.
Medtronic has announced a final exchange ratio of 4.5939 for its exchange offer of ordinary shares for shares of MiniMed Group, Inc. The offer allows shareholders to exchange up to 225 million shares of MiniMed stock. The exchange offer will expire on October 9, 2026, unless extended or terminated. This strategic move is part of Medtronic's efforts to separate MiniMed as an independent entity.
Read more →MDT▲ +1.8%today
Blink Anesthesia, maker of the TwitchView® quantitative neuromuscular monitor, names Medtronic veteran Lindsay Boyle VP of Commercial Operations
Blink Anesthesia has appointed Lindsay Boyle as VP of Commercial Operations, where she will oversee sales and marketing efforts for the TwitchView® Train of Four Monitor. With 20 years of experience at Medtronic, Boyle aims to enhance the adoption of neuromuscular monitoring technology. Her leadership is expected to drive the company's mission of improving patient safety in anesthesia care.
Read more →MDTMedtronic Receives Category I CPT® Code Approvals for Altaviva™ and Symplicity Spyral™ Systems
Medtronic has received Category I CPT code approvals for its Altaviva and Symplicity Spyral systems, enhancing reimbursement pathways for these innovative treatments. The Altaviva device addresses urge urinary incontinence, while the Symplicity Spyral system targets uncontrolled hypertension. These approvals are effective January 2028 and signify growing clinical support and adoption among physicians.
Read more →MDTMedtronic announces regulatory milestones for newest cardiac mapping and ablation software
Medtronic has achieved significant regulatory milestones with the FDA clearance and CE Mark for its Affera Prism-2 Mapping Software and PulseSelect ProxBox Adapter. These advancements enhance cardiac mapping capabilities and provide real-time feedback during ablation procedures. The new software tools aim to improve the precision of cardiac procedures and support better patient outcomes.
Read more →MDTMedtronic announces FDA clearance for LigaSure™ RAS Maryland instrument on the Hugo™ RAS system
Medtronic has announced FDA clearance for the LigaSure RAS Maryland instrument, designed for use with the Hugo robotic-assisted surgery system. This clearance allows U.S. surgeons to utilize a trusted vessel-sealing technology that has been effective in over 45 million procedures worldwide. The instrument aims to enhance surgical performance and meet the growing demand for robotic-assisted surgeries.
Read more →MDTSonus Microsystems and Medtronic Partner to Advance AI-Powered Maternal Health Monitoring
Sonus Microsystems has partnered with Medtronic to integrate the Sonus Patch, an AI-powered wearable ultrasound, with Medtronic's technology. This collaboration will focus on non-invasive monitoring of pregnant women at risk of preeclampsia in Kenya. The project aims to provide accessible cardiac monitoring and improve maternal health outcomes.
Read more →MDTMedtronic Launches Exchange Offer to Complete Separation of MiniMed Group, Inc.
Medtronic has initiated an exchange offer to separate at least 80.1% of MiniMed Group, Inc., allowing shareholders to exchange their Medtronic shares for MiniMed stock. This move is expected to be tax-free for U.S. federal income tax purposes. The exchange offer reflects Medtronic's confidence in MiniMed's future as an independent company, while allowing Medtronic to concentrate on its other business segments.
Read more →MDTMedtronic executives to speak at upcoming investor conferences
Medtronic plc will participate in two upcoming investor conferences, featuring CEO Geoff Martha and CFO Thierry Piéton. The Wells Fargo Healthcare Conference is scheduled for September 8, 2026, and the Morgan Stanley Global Healthcare Conference will follow on September 15, 2026. Live webcasts will be available for both events.
Read more →MDTCornerstone Robotics gibt strategische Partnerschaft mit Medtronic bekannt, um den weltweiten Zugang zu robotergestützter Chirurgie zu erweitern
Cornerstone Robotics has announced a strategic partnership with Medtronic, involving a $700 million investment from Medtronic. This collaboration aims to enhance global access to robotic surgery through the distribution of Cornerstone's Sentire™ surgical system in select markets. The partnership is expected to bridge the gap in minimally invasive surgical technology availability worldwide.
Read more →MDTCornerstone Robotics anuncia una alianza estratégica con Medtronic
Cornerstone Robotics has announced a strategic partnership with Medtronic to enhance global access to robotic surgery. Medtronic will invest approximately $700 million and gain distribution rights for Cornerstone's Sentire surgical system in select markets. This collaboration aims to bridge the gap in access to advanced minimally invasive surgical care worldwide.
Read more →MDTCornerstone Robotics Announces Strategic Partnership with Medtronic to Expand Global Access to Robotic-assisted Surgery
Cornerstone Robotics has formed a strategic partnership with Medtronic, which includes a $700 million investment. This collaboration aims to enhance global access to robotic-assisted surgery, leveraging Medtronic's distribution capabilities and Cornerstone's innovative technology. The Sentire surgical system has received approvals in several regions, indicating its readiness for broader market adoption.
Read more →MDTMedtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance
Medtronic plc reported strong financial results for Q1 FY27, with revenues of $9.8 billion, reflecting a 13.7% increase. The company raised its guidance for organic revenue growth and diluted EPS for the fiscal year. Notable growth was seen in the cardiovascular and neuroscience segments, driven by strategic investments and acquisitions. CEO Geoff Martha expressed confidence in the company's long-term growth trajectory.
Read more →MDTMedtronic Announces Strategic Partnership with Cornerstone Robotics to Further Expand Global Access to Robotic-Assisted Surgery
Medtronic has announced a strategic partnership with Cornerstone Robotics, investing approximately $700 million to distribute the Sentire surgical system in select markets outside the U.S. This collaboration aims to enhance global access to robotic-assisted surgery by combining Sentire with Medtronic's existing Hugo system. The partnership is expected to significantly improve surgical options for health systems and patients worldwide.
Read more →MDTMedtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
Medtronic has announced a strategic investment in Pi-Cardia to enhance its structural heart portfolio, focusing on complex transcatheter aortic valve replacement (TAVR) procedures. The investment includes up to $80 million and an option to acquire Pi-Cardia for up to $210 million. The ShortCut device, developed by Pi-Cardia, is the first FDA-cleared technology for leaflet modification in valve-in-valve TAVR, aiming to improve procedural outcomes.
Read more →MDTMedtronic announces cash dividend for second quarter of fiscal year 2027
Medtronic plc has declared a cash dividend of $0.72 per ordinary share for the second quarter of fiscal year 2027. This decision aligns with the company's previous announcement of a dividend increase in June 2026. The dividend is set to be paid on October 16, 2026, to shareholders recorded by September 25, 2026.
Read more →MDTMedtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias
Medtronic has announced an expanded CE Mark indication for its Affera Mapping and Ablation System with the Sphere-9 Catheter, now approved for treating ventricular arrhythmias. This milestone is significant for patients suffering from conditions like ventricular tachycardia and premature ventricular complexes. The Sphere-9 catheter is recognized for its innovative design and dual-energy capabilities, which enhance treatment efficacy. Additionally, the FDA has granted Breakthrough Device Designation for the Sphere-9, expediting its regulatory approval process in the U.S.
Read more →MDTA new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026
Medtronic is set to unveil its Touch Surgery™ Aide platform at the Society of Robotic Surgery 2026. This AI-native surgical computing platform will enhance real-time decision-making during procedures, supported by NVIDIA's advanced computing infrastructure. The platform aims to improve surgical workflows and patient outcomes, marking a significant advancement in robotic surgery technology.
Read more →MDTMedtronic to announce financial results for its first quarter of fiscal year 2027
Medtronic plc will announce its financial results for the first quarter of fiscal year 2027 on September 1, 2026. The announcement follows the end of the quarter on July 31, 2026. A news release will be issued early in the morning, followed by a video webcast to discuss the results. A replay will be available shortly after the webcast.
Read more →MDTMedtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
Medtronic has completed the acquisition of SPR Therapeutics for $650 million, enhancing its pain therapy portfolio with the SPRINT® PNS technology. This non-opioid treatment option aims to improve patient access to pain management solutions for chronic and acute pain. The SPRINT® system has shown promising clinical results, with a significant percentage of patients experiencing meaningful pain relief.
Read more →MDTMedtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Medtronic has successfully acquired Scientia Vascular for $550 million, enhancing its neurovascular product portfolio. The integration of Scientia's access technologies aims to simplify complex procedures and improve efficiency for physicians. This strategic acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 and accretive thereafter.
Read more →About Medtronic plc.
HeadquartersBUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY, H91 4K49
BIOPHARMAWATCH ELITE PLUS
Trade the next MDT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime